Nakagawara A, Ikeda K, Tsuda T, Higashi K, Okabe T
J Pediatr Surg. 1987 May;22(5):415-8. doi: 10.1016/s0022-3468(87)80260-9.
The amplification of N-myc oncogene is frequently observed in tumors of patients with advanced, poor prognostic stages of neuroblastoma (unfavorable stage group). However, there has been little documentation of the N-myc amplification in tumors of patients with stages II and IVS neuroblastoma (favorable stage group). In this communication, we present data on one patient in stage II and two in stage IVS. In these children, the primary tumors had an amplified N-myc and the clinical course was poor. In addition, from an analysis of the N-myc oncogene of 26 neuroblastomas, genomic amplification of more than three copies was observed in 4 of 11 (36%) in the favorable stage group, and in 9 of 15 (60%) in the unfavorable stage group. Death occurred only in those with an amplified N-myc, in both groups. The smaller copy number of N-myc amplification of stage IVS tumors as compared with those of stages III and IV, appeared to be characteristic. These findings suggest that N-myc amplification may be a reliable prognostic indicator even in the favorable stage group of neuroblastomas, and may be clinically useful as a guide for treating those with a poor prognosis in stages II and IVS.
在晚期预后不良的神经母细胞瘤（高危期组）患者的肿瘤中，经常观察到N - myc癌基因的扩增。然而，关于Ⅱ期和ⅣS期神经母细胞瘤（低危期组）患者肿瘤中的N - myc扩增，几乎没有文献记载。在本报告中，我们展示了1例Ⅱ期患者和2例ⅣS期患者的数据。在这些儿童中，原发肿瘤存在N - myc扩增，且临床病程不佳。此外，通过对26例神经母细胞瘤的N - myc癌基因分析，在低危期组的11例中有4例（36%）观察到超过三个拷贝的基因组扩增，在高危期组的15例中有9例（60%）观察到。两组中，只有那些N - myc扩增的患者死亡。与Ⅲ期和Ⅳ期肿瘤相比，ⅣS期肿瘤的N - myc扩增拷贝数较少似乎是其特征。这些发现表明，即使在神经母细胞瘤的低危期组中，N - myc扩增也可能是一个可靠的预后指标，并且在临床上可作为治疗Ⅱ期和ⅣS期预后不良患者的指导依据。
